Oncogenic activation of K-ras occurs commonly in non-small cell lung cancer (NSCLC), but strategies to therapeutically target this pathway have been challenging to develop. Information about downstream effectors of K-ras remains incomplete, and tractable targets are yet to be defined. In this study, we investigated the role of protein kinase C d (PKCd) in K-ras-dependent lung tumorigenesis by using a mouse carcinogen model and human NSCLC cells. The incidence of urethane-induced lung tumors was decreased by 69% in PKCd-deficient knockout (dKO) mice compared with wild-type (dWT) mice. dKO tumors are smaller and showed reduced proliferation. DNA sequencing indicated that all dWT tumors had activating mutations in KRAS, whereas only 69% of dKO tumors did, suggesting that PKCd acts as a tumor promoter downstream of oncogenic K-ras while acting as a tumor suppressor in other oncogenic contexts. Similar results were obtained in a panel of NSCLC cell lines with oncogenic K-ras but which differ in their dependence on K-ras for survival. RNA interferencemediated attenuation of PKCd inhibited anchorage-independent growth, invasion, migration, and tumorigenesis in K-ras-dependent cells. These effects were associated with suppression of mitogen-activated protein kinase pathway activation. In contrast, PKCd attenuation enhanced anchorage-independent growth, invasion, and migration in NSCLC cells that were either K-ras-independent or that had WT KRAS. Unexpectedly, our studies indicate that the function of PKCd in tumor cells depends on a specific oncogenic context, as loss of PKCd in NSCLC cells suppressed transformed growth only in cells dependent on oncogenic K-ras for proliferation and survival. Cancer Res; 71(6); 2087-97. Ó2011 AACR.
Introduction
Non-small cell lung cancers (NSCLC) account for the majority of lung cancers, with adenocarcinomas being the predominant subtype (1) . Mutation of KRAS occurs in about 30% of lung adenocarcinomas, resulting in its constitutive activation (2) . To identify potential downstream effectors of oncogenic K-Ras, we have explored the contribution of protein kinase C d (PKCd) to K-Ras-dependent lung tumorigenesis. The PKC family of serine/threonine protein kinases consists of 11 isoforms that regulate a wide variety of biological functions (3) . Studies in PKCd knockout (dKO) mice have confirmed a role for this kinase in cell proliferation and apoptosis (3) (4) (5) (6) (7) (8) (9) (10) . In the dKO mouse, cell death in response to irradiation is suppressed, and smooth muscle and epithelial cells cultured from these mice are resistant to multiple apoptotic stimuli (5, 7, 11) . PKCd may regulate apoptosis via p53, as p53 transcriptional activation in response to genotoxins and oxidative stress requires PKCd (12) (13) (14) (15) . In the context of proliferation, PKCd has been shown to be a downstream effector of the epidermal growth factor receptor (EGFR; refs. 6, [16] [17] [18] and collaborates with the Hedgehog pathway to regulate extracellular signal regulated kinase (ERK) signaling (19) . PKCd has also been shown to both positively and negatively regulate cell-cycle progression (19, 20) .
The demonstration of a proapoptotic role for PKCd has lead to the suggestion that it may function as a tumor suppressor (3, 21) . In support of this, PKCd protein expression is reduced in human squamous cell and bladder carcinomas (22, 23) and decreases with increasing tumor grade in human endometrial carcinomas (24) . In contrast, PKCd expression is elevated in pancreatic cancer, myelogenous leukemia, and hepatocellular carcinoma (25) (26) (27) . To address these potentially diverse functions of PKCd, we have used a chemically induced mouse model in which lung tumorigenesis is associated with activating mutations in KRAS, and a panel of human NSCLC cells that harbor oncogenic K-ras. Our studies show that PKCd functions as a tumor promoter in transformed cells that are dependent on K-ras for proliferation and survival whereas, in tumor cells that do not rely on K-ras, PKCd may function as a tumor suppressor.
Materials and Methods

Animal models
FVB dKO mice were generated by backcrossing C57/Bl6 dKO mice (28) with FVB mice for more than 10 generations. Nude mice were purchased from Jackson Laboratories. Animals were maintained at the University of Colorado, Denver Anschutz Medical Campus, in accordance with Laboratory Animal Care guidelines and protocols and with approval of the University of Colorado, Denver Institutional Animal Use and Care Committee. Male FVB dWT and dKO mice (6-8 weeks of age) were injected with 1 mg/kg urethane in sterile water and sacrificed at 10 or 20 weeks postinjection. Mice were perfused with 10 mL of sterile-filtered heparinized PBS (500 U/mL), and the lungs were inflated with 10% formalin. Fixed lungs were processed and paraffin embedded or were stored for DNA extraction at À80 C.
Tumor analysis
Tumor sections (5 mm) were stained with hematoxylin and eosin (H&E) and anti-Ki67 as previously described (5) . Quantification of tumors at 20 weeks was done by counting macroscopic tumors in dissected lungs. Tumor diameter was measured using digital microcalipers; because of the spherical shape of the tumors, tumor volume was calculated using the formula 4/3pr 3 . For quantification of microscopic tumors at 10 weeks, paraffin-embedded tumors were cut into sequential 4 mm thick sections and stained with H&E. Tumor number was determined by analysis of sections, representing the entire lung, by light microscopy. Tumor volume was determined using the formula 4/3pr 3 , where tumor diameter equaled 4 mm Â the number of sections the tumor spanned.
Sequencing of KRAS in urethane-induced tumors
DNA was extracted using the DNeasy Blood and Tissue Kit and the Qiacube Automated Extraction System (Qiagen). Exons 2 and 3 of the mouse KRAS gene were sequenced using the Applied Biosystems Incorporated Big Dye Cycle Sequencing Kit and ABI 3730 Sequencer. The following primer sets were used: NSCLC cell lines, A549, NCI-H2009, NCI-H441, NCI-H727,  NCI-H460, SW1573 , Colo699, and NCI-H226, were acquired from the University of Colorado Denver Lung SPORE Cell Bank. Cell line profiling for authentication was done at the DNA Sequencing Core at University of Colorado Anschutz Medical Campus by using the ABI profiler plus and ABI identifier profiling kits. Cells were maintained in RPMI-1640 with 2 mmol/L L-glutamine and 10% FBS. Transient depletion of PKCd by siRNA was done using ON-TARGETplus SMARTpool siRNA for human PKCd (Dharmacon; Thermo Fisher) consisting of the following sequences: 5 0 -CCAUGUAUCCUGA-GUGGAA, 5 0 -CCAAGGUGUUGAUGUCUGU, 5 0 -AAAGAACG-CUUCAACAUCG, and 5 0 -CCGCACCGCUUCAAGGUUC, and the ON-TARGETplus Nontargeting Pool. Stable depletion of PKCd was done using lentiviral constructs containing short hairpin (shRNA) to human PKCd (Open Biosystems; pLKO-TRC00010193 or pLKO-TRC00010203) or an shRNA control (pLKO-scrambled). Lentiviral particle containing media was prepared as previously described (29) . NSCLC cell lines were infected with 1 mL of lentiviral particle containing media plus 500 mg/mL polybrene for 1 hour, followed by the addition of complete media. Cell lines were maintained in selection media with 2 mg/mL puromycin and used at low passage (<8). Stable depletion of K-ras was done using lentiviral constructs as described (30) .
Cell proliferation and anchorage-independent growth
Cells were plated at low density and harvested for determination of cell number at days 1 to 6 post plating. For analysis of cell proliferation by bromodeoxyuridine (BrdU) incorporation, 0.5 Â 10 4 cells per well were grown in 96-well plates and transiently depleted of PKCd by using pooled siRNA as described earlier. After 72 hours, proliferating cells were labeled with 10 mmol/L 5-bromo-2 0 -deoxyuridine for 2 hours. BrdU incorporation was detected using the cell proliferation ELISA kit (Roche Applied Science). A WST-1 proliferation kit was used according to the manufacturer's specification for analysis of cell proliferation in cells depleted of K-Ras (Roche Applied Science). To assay anchorage-independent growth, NSCLC lung cancer cell lines were suspended (0.5 Â 10 4 to 5 Â 10 4 cells per well) in a top layer of 0.36% noble agar (USB Corporation) in RPMI-1640 þ 10% FBS and a bottom layer of 0.4% noble agar in RPMI-1640 þ 10% FBS in 6-well multiplate tissue culture dishes. After 1 to 6 weeks, colonies were stained with NBT (Sigma), photographs were taken with a S600 Canon camera, and colonies were quantified using MetaMorph software (Molecular Devices).
Invasion and migration
Boyden chambers (BD Biosciences) with Matrigel coating were used for invasion assays; chambers without Matrigel were used for migration assays. Cells (5 Â 10 4 ) were plated in serum-free media in the top chamber, whereas media containing 10% serum was added to the bottom chamber. After 22 hours, cells were fixed in 10% normal buffered formalin and stained with crystal violet. Cells that did not migrate or invade through the filters were then scraped off, and the remaining migrated/invaded cells were counted. Five fields (200Â magnification) were counted for each filter; each experimental condition was assayed on triplicate filters.
Ras pull-down assay
Cell lysates were prepared using the Ras activation assay kit from Millipore and precleared with 50 mL of packed glutathione sepharose 4B (GE Healthcare) per 500 mL of lysate. For controls, lysates plus GTPgS (positive) or GDP (negative) were used. For the Ras pull-down, 350 mL of precleared lysate was transferred to a tube containing 10 mg of PBD-Pak1 agarose and incubated for 1 hour at 4 C. Pellets were washed, resuspended in 2Â Laemmli sample buffer, and separated by SDS-PAGE. Proteins were detected by immunoblotting for Ras as described in the following text.
Adenovirus infection
NSCLC cells were plated at 1 Â 10 6 cells per 60-mm dish. The following day cells were infected with either the Ad-LacZ control or Ad-PKCdKD adenovirus at an MOI (multiplicity of infection) ¼ 250 as previously described (10) . Cells were harvested for protein 24 hours post transduction and ran on a 10% SDS-polyacrylamide gel. Proteins were immobilized on polyvinylidene difluoride membrane and then immunoblotted for the indicated proteins.
Immunoblot analysis
Immunoblotting was done as previously described (5). Antibodies to PKCd (sc-937) and actin (sc-1616) were purchased from Santa Cruz Biotech. The following antibodies were purchased from Cell Signaling Technologies: phospho-Akt (#4060; pAkt); Akt (#9272); phospho-ERK1/2 (#9101; pERK1/2); ERK1/2 (#4695); phospho-MEK (MAP/ ERK kinase) 1/2 (#9121; pMEK;); MEK1/2 (#9122); phospho-PDK1 (#3061; pPDK1;); PDK1 (#3062). Anti-Ras was purchased from Millipore and antibodies to RSK1 and phospho-RSK1 (#AF889; pRSK90;) were purchased from R&D Systems.
Growth of H441 cells as xenografts
Nude mice were injected with control [scrambled shRNA control (scr); n ¼ 10] H441 cells in the left flank or H441 cells expressing either d193 (n ¼ 5) or d203 (n ¼ 5) in the right flank. Tumors were measured using digital microcalipers every second day starting at day 9, and tumor volume was calculated using the formula p/6 (L Â 0.5L 2 ). Mice were sacrificed at day 27, and tumor lysates were immunoblotted for pERK and stripped and reprobed for total ERK or immunoblotted for PKCd and stripped and reprobed for actin.
Results
Reduced urethane-induced lung tumorigenesis in the dKO mouse
To determine whether PKCd contributes to lung tumorigenesis, we analyzed the development of urethane-induced tumors in mice in which the PKCd gene has been disrupted (dKO) and in their wild-type (dWT) littermates. As shown in Figure 1A , lung tumors in dKO mice treated with urethane for 20 weeks were reduced by 69% compared with dWT mice, with an average of 13.1 AE 1.1 tumors per dWT mouse and 4.1 AE 0.7 tumors per dKO mouse (P < 0.0001). Tumors from both genotypes resembled well-differentiated adenomas; however, tumors from dKO mice were significantly smaller than those from dWT mice (Fig. 1B and C, top) . Expression of the proliferation marker Ki67 was reduced by 30% in dKO tumors as compared with dWT tumors (Fig. 1C, bottom) . Cells positive for cleaved caspase-3 were only very rarely observed in any tumors (data not shown), suggesting that aberrant regulation of apoptosis is unlikely to explain the reduced lung tumorigenesis in dKO mice.
The dramatic reduction in tumor number in dKO mice could result from delayed tumor growth or possibly tumor regression. To address this further, we analyzed tumor number and size in dKO and dWT mice at 10 weeks following urethane treatment (Fig. 1D ). Microscopic and macroscopic tumors were apparent in the lungs of both genotypes; 6 of 7 dWT mice had 3 or more tumors, whereas only 2 of 7 dKO mice had a similar tumor burden. This suggests a trend toward reduced tumor number in dKO mice; however, tumor number per mouse was not statistically different between the 2 groups (Fig. 1D, top) . In contrast, a statistically significant reduction in tumor size was seen in 10-week urethane-treated dKO mice (Fig. 1D, bottom) . In addition, although tumors greater than 2.5 Â 10 6 mm 3 comprised 40% of the tumors found in dWT mice, this population was absent from the dKO mice. This suggests that in the absence of PKCd, urethaneinduced tumors either do not progress or progress more slowly.
To determine the KRAS mutational status of dWT and dKO tumors, we sequenced exons 2 and 3 of KRAS, which contain the codons (12, 13, and 61) most frequently mutated in lung cancer. All 20 tumors analyzed from dWT mice had oncogenic mutations in codon 61 of KRAS. No mutations in codons 12 or 13 were found. The reduction in urethane-induced tumors in dKO mice suggests that in the context of oncogenic KRAS, PKCd functions as a tumor promoter. However, only 22 of 32 tumors sequenced from dKO mice had KRAS codon 61 mutations (P < 0.008; Table 1 ). Hence, more than 30% of the dKO tumors arise via a K-Ras-independent mechanism. Furthermore, as WT KRAS tumors are found only in dKO mice, in this subset of tumors loss of PKCd seems to be permissive for tumorigenesis, suggesting that in some oncogenic contexts PKCd may function as a tumor suppressor.
PKCd is required for transformed growth of human KRas-dependent NSCLC cells
Although many NSCLC cell lines harbor oncogenic KRAS, recent studies from Settleman and colleagues show that only a subset of these cells continue to require activated K-Ras for proliferation and survival (30) . To determine the role of PKCd in transformed growth, we used a panel of NSCLC cell lines that are dependent on activated K-Ras for survival (H2009, H441, and H727), independent of K-Ras for survival (A549, H460, and SW1573), or express WT K-Ras protein (Colo669 and H226). The K-Ras dependency of these cell lines for growth was verified in cells depleted of K-Ras. As reported previously, H2009 and H441 cells were highly dependent on KRas for growth whereas H727 cells were only slightly dependent (Supplementary Fig. 1; ref. 30 ). PKCd expression in these 8 NSCLC cell lines and a human cell line derived from normal Significance for all experiments was determined using a 2-tailed Student's t test.
bronchial epithelial cells does not correlate per se with the presence of, or dependence on, activated K-Ras (Supplementary Fig. 2A) .
To determine the effect of PKCd depletion on growth of NSCLC cells as monolayers, PKCd was transiently depleted by transfection of pooled targeted siRNAs. Assay of BrdU incorporation 72 hours after the addition of siRNA indicated that the proliferation of A549 cells was slightly, but significantly, increased by depletion of PKCd; however, PKCd depletion had no effect on the proliferation of any of the other NSCLC cell lines (Fig. 2A) . When PKCd was depleted with shRNA and cell growth was assayed by counting cells on successive days, depletion of PKCd had no effect on cell proliferation ( Supplementary Fig. 2B-D) . Anchorage-independent growth of cancer cells is a marker of transformed growth in vitro and correlates with tumor aggressiveness and metastatic potential in vivo (31) . To assay the effect of PKCd depletion on anchorage-independent growth, we depleted PKCd in NSCLC cells by a lentiviral delivery of shRNA directed to PKCd (d193 and d203) or a scrambled shRNA control. d193 expression resulted in nearly complete depletion of PKCd in all cell lines, whereas d203 resulted in partial depletion of PKCd protein (Fig. 2B and C and Supplementary Fig. 2B ). Neither of the shRNAs altered the expression of other PKC isoforms (data not shown). As shown in Figure 2B , depletion of PKCd suppressed colony formation in soft agar by 60% to 80% in 3 K-Ras-dependent NSCLC cell lines (H2009, H441, and H727). A fourth K-Rasdependent cell line, H358, showed a 55% decrease in anchorage-independent growth in cells expressing d193 shRNA as compared with scrambled shRNA (data not shown). In contrast, the K-Ras-independent cell lines (A549 and H460) and the K-Ras WT cells (H226) showed a small but significant increase in colony formation when PKCd was depleted, suggesting that PKCd suppresses anchorage-independent cell growth in this subset of NSCLC cell lines (Fig. 2B) .
PKCd regulates MAPK signaling in NSCLC cells
To probe the mechanism by which PKCd regulates transformed growth of K-Ras-dependent NSCLC cells, we investigated activation of the mitogen-activated protein kinase (MAPK) and Akt pathways, both of which are known to drive proliferation downstream of oncogenic K-ras. No significant differences were found in the amount of activated Ras between the control cell lines and cell lines in which PKCd had been depleted (Fig. 3A) . As PKCd has previously been implicated in regulation of PDK1 (32) , an upstream activator of Akt, we next investigated whether PDK1 and/or Akt activation was regulated by PKCd. As shown in Figure 3B , although Akt activation varies between the NSCLC cell lines, neither PDK1 nor Akt was regulated by depletion of PKCd.
Analysis of the MAPK pathway revealed that depletion of PKCd suppresses proliferative signaling via this pathway dramatically in K-Ras-dependent H2009 and H441 cells (Fig. 4A) . Phosphorylation of MEK was suppressed in H2009 and H441 cells depleted of PKCd, especially in cells expressing the d193 shRNA, as was phosphorylation of its downstream target, ERK (quantified in Fig. 4B and C) . Depletion of PKCd in the H727 cells had only a slight effect on ERK activation and seemed to increased pMEK, perhaps reflecting the observation by our laboratory and that of Singh and colleagues that these cells are intermediate Figure 3 . PKCd is not required for activation of Ras or PDK1/Akt in NSCLC cells. A, Ras activation in control (scr), d193, and d203 expressing A549, H2009, and H441 cells. Top, pull-down of GTP-bound Ras; far left, GTPgS or GDP was added to cell lysates before pull-down. Second, third, and fourth rows show immunoblots for total Ras, PKCd, and actin. B, cell lysates prepared from control (scr), d193, and d203 expressing K-Ras-independent (A549 and H460) and K-Rasdependent (H2009 and H441) NSCLC cells were immunoblotted for pPDK1 (S241), pAkt (S473), pMEK1/2 (S217/221) as indicated. Blots were stripped and probed for total PDK1, Akt, PKCd, and actin, as indicated. Experiments were repeated a minimum of 4 times.
between K-Ras-dependent and K-Ras-independent NSCLC cells (Supplementary Fig. 1A; ref. 30) . Phosphorylation of RSK90, a downstream target of activated ERK, was also slightly suppressed in PKCd-depleted H727, H2009, and H441 cells, although this was some what variable, perhaps reflecting the fact that multiple pathways can regulate RSK90. In contrast to K-Ras-dependent cells, depletion of PKCd in K-Ras-independent A549, H460, and SW1573 cells resulted in an increase in phospho-MEK, which correlated with a more robust activation of ERK (Fig. 4A-C) . Regulation of ERK activation by PKCd was verified by transducing A549, H460, H2009, and H441 cells with an adenovirus encoding a kinase dead (dKD) PKCd which functions as dominant negative (10) . A decrease in pERK was found only in the K-Ras-dependent H2009 and H441 cells, whereas a small increase in pERK was observed in the K-Ras-independent A549 cells. These studies indicate that PKCd positively regulates proliferative signaling through the MEK/ERK pathway in K-Ras-dependent NSCLC cells whereas in K-Rasindependent cells PKCd may suppress this proliferative pathway.
Depletion of PKCd suppresses invasion, migration, and tumor growth in nude mice
As PKCd has been shown to regulate motility and invasion of breast carcinoma cells through regulation of the ERK pathway (33), we next sought to determine whether depletion of PKCd suppresses the ability of A549 or H2009 cells to Figure 4 . PKCd is required for the activation of MEK/ERK in NSCLC cells that are K-ras-dependent for survival. A, cell lysates prepared from control (scr), d193, and d203 expressing K-Ras-mutated NSCLC cells were immunoblotted for pMEK1/2 (S217/221), pERK1/2 (T202/Y204), and pRSK90 (S380). Blots were stripped and probed for total MEK1/2, ERK1/2, RSK90, PKCd, and actin, as indicated. Representative experiments are shown; experiments were repeated a minimum of 4 times. B, pMEK1/2 levels from A were quantified by densitometry, normalized to total MEK1/2, and plotted relative to control (scr). C, pERK1/2 levels from A were quantified by densitometry, normalized to total ERK1/2, and plotted relative to control (scr). For B and C: scr, white bars; d193, gray bars; d203, black bars. D, A549, H460, H2009, and H441 cells were infected with adenovirus encoding either control (Ad-lacZ) or kinase dead (Ad-dKD). Cell lysates were prepared and immunoblotted for pERK1/2, ERK, actin, and PKCd. Increased PKCd protein in dKD transduced cells indicates expression of dKD. This experiment was repeated 3 times; a representative blot is shown.
migrate in response to serum or to invade through a Matrigel cushion. As shown in Figure 5A , depletion of PKCd significantly suppressed cell migration (up to 50%) and invasion (up to 70%) in H2009 cells as compared with cells expressing a scrambled shRNA. In contrast, no inhibition of migration or invasion was seen in PKCd-depleted A549 cells (Fig. 5B) . This indicates that similar to anchorage-independent growth, PKCd regulates invasion and migration of NSCLC cells only in the context of dependency on activated K-Ras.
To investigate whether depletion of PKCd alters the tumorigenicity of NSCLC cells in vivo, K-Ras-dependent H441 cells expressing scrambled shRNA, d193, or d203 were injected in contralateral flanks of nude mice and tumor size was measured beginning at day 9 postinjection. Tumors from H441 cells expressing the d193 construct were smaller than those expressing the scrambled control at all time points (40%-80%), but this difference was not significant until day 19. Tumors derived from H441 cells expressing the d203 construct also showed reduced growth compared with the scrambled Figure 5 . Depletion of PKCd suppresses invasion, migration, and tumor growth in nude mice. Migration and invasion of control (scr), d193-, or d203-expressing H2009 (A) and A549 (B) cells was assayed as described in Materials and Methods. Five fields were counted for each filter, and each experimental condition was assayed on triplicate filters. Each experiment was repeated 3 or more times. C, top, nude mice were injected with control H441 cells (diamonds; n ¼ 10) in the left flank or H441 cells expressing either d193 (triangles; n ¼ 5) or d203 (squares; n ¼ 5) in the right flank. Tumors were measured starting on day 9. Graphs show average of measurements AE SEM. *, significantly different from d203 shRNA control (40%-60%); however, in this case, the difference was only significant until day 17 (Fig. 5C, top) . To verify that PKCd depletion is sustained in the tumors, tumor lysates were prepared when mice were sacrificed at day 27 and probed for PKCd expression (Fig. 5C, bottom) . Analysis of pERK in these tumor lysates indicated that the reduction in ERK activation observed in vitro was also maintained during tumor growth in vivo (Fig. 5C, bottom) , suggesting that reduced tumor growth is coupled to reduced proliferative signaling via this pathway.
Discussion
The development of new therapeutics to target the K-Ras pathway depends on the identification of specific mediators of K-Ras-dependent tumorigenesis. Although a number of laboratories have defined oncogenic K-ras gene signatures (34) (35) (36) , the molecular effectors of K-Ras that drive transformation and proliferation in NSCLC are still largely unknown. Our studies suggest that PKCd functions as a tumor promoter in the context of oncogenic K-ras, as it is required for urethane-induced lung tumorigenesis and for transformed growth of a subset of NSCLC cell lines that are dependent on activated K-Ras for survival. Conversely, PKCd may suppress tumorigenesis through other oncogenic pathways, as urethane-induced tumors with WT KRAS arise in the absence of PKCd and transformed growth of K-Ras-independent NSCLC cells is enhanced when PKCd is depleted.
Our studies suggest that in the urethane-induced tumor model, PKCd is required for the progression of K-Ras-driven lung tumors and hence functions as a tumor promoter. Likewise, depletion of PKCd suppresses growth of K-Ras-dependent NSCLC cells in soft agar and inhibits migration and invasion, confirming that this kinase is functionally important for the malignant phenotype. On the basis of our observation that urethane-induced tumors are decreased dramatically in dKO mice, together with the finding that 31% of the tumors that arise do not have KRAS mutations, the probability of oncogenic K-ras driving tumorigenesis in dKO mice seems to be reduced nearly 5-fold. This is consistent with a recent study by Mauro and colleagues, which shows that overexpression of PKCd can promote tumorigenesis in a mouse model of human pancreatic cancer, the majority of which harbor oncogenic KRAS (37). Studies from Xia and colleagues likewise show that PKCd is required for survival signaling of 3T3 cells expressing activated K-Ras, albeit in these cells PKCd seems to regulate AKT signaling downstream of activated K-Ras, whereas our studies suggest that PKCd regulation of MEK/ERK may be more critical for NSCLC cells (32, 38) . Of note, Fields and colleagues have shown that atypical PKCi is an oncogene in human NSCLC cells. Interestingly, amplification of PKCi seems to occur primarily in squamous cell carcinomas, a subtype of NCSLC that do not typically have activated K-Ras (39) .
A particularly novel outcome of our studies is the finding that 31% of the urethane tumors in dKO mice do not have activating mutations in KRAS. We propose that in this group of tumors PKCd functions as a tumor suppressor. Similarly, our studies suggest that in K-Ras-independent NSCLC cell lines, loss of PKCd enhances transformed growth and proliferative signaling, again suggesting a role as a tumor suppressor. Taken together, this suggests that alternative proliferative pathways that are normally suppressed by PKCd may sustain growth in K-Ras-independent NSCLC cell lines and in the subset of urethane tumors that do not have mutated KRAS. In this regard, preliminary data from our laboratory indicates that about 10% of this later group of tumors have mutations in codon 20 of PIK3CA (data not shown). Future studies are needed to characterize these mutations and to understand why they are seen only in the context of the dKO mouse. Activating mutations in components of the PTEN/Akt pathway have recently been reported in a small subset of human lung cancers (40) . Curiously, in some cells these mutations occur in conjunction with mutation of KRAS, suggesting a mechanism by which K-Ras-dependent cancer cells may become K-Ras independent for proliferation and survival. Singh and colleagues report that in pancreatic cancer cell lines with oncogenic KRAS, K-Ras independence correlates with increased activation of Akt; however, this correlation does not hold true for the subset of NSCLC cell lines examined in this study (36) . Instead, in the K-Ras-independent NSCLC cell lines, depletion of PKCd increases the activation of MEK/ERK. Several mechanisms, including regulation of the ERK phosphatase MKP3 or interaction of PKCd with the adaptor protein Sprouty 2 (41, 42) , have been suggested for PKCd regulation for MEK/ERK.
In addition to its well-established role in apoptosis, our current studies support a role for PKCd in cell survival and transformation and begin to define the molecular context for these seemingly disparate functions of PKCd. An important question is what "switches" PKCd from its proapoptotic role to its prosurvival/transformation role. We propose that in KRas-dependent cells, PKCd function to integrate cell proliferation and survival signals through regulation of MEK/ERK signaling (Fig. 5D) . In other cells, particularly in nontransformed cells, and in K-Ras-independent NSCLC cells, PKCd may functions primarily to regulate apoptosis and suppress proliferation. The plasticity of PKCd signaling in lung cancer cells illustrates the need to understand the genetic context of specific cancer subtypes so as to more accurately target therapies.
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